MedTrace Logo

A Study of IMC008 for Advanced Solid Tumors

NCT05837299 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-05-01

No results posted yet for this study

Summary

An open label, multi-center, dose-escalating study to evaluate the safety and preliminary efficacy of IMC008 in CLDN18.2 positive advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

IMC008

allowing 10% dose error

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Tianhang Luo, MD · Changhai Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-02
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05837299 on ClinicalTrials.gov